Choreo LLC trimmed its stake in Piper Sandler Companies (NYSE:PIPR – Free Report) by 32.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.

According to Piper Sandler analysts, the initiative is set to ease regulatory uncertainties that have long deterred institutional players from entering or expanding in the digital asset market.

Piper Sandler adjusted its model to reflect fourth-quarter and full-year 2024 earnings, 2025 guidance, and industry checks on raw material costs, construction activity, and export markets. It ...

Shares of Piper Sandler Companies stock opened at $319.81 on Monday. The business has a 50 day moving average price of $302.86 and a 200 day moving average price of $314.09. The company has a ...

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, announced today that its board of directors has authorized the repurchase of up to $150 million of ...

Craig W. Johnson, chief market technician at Piper Sandler, said that these shares are “retesting the neckline of an inverted head and shoulders formation,” as relative strength has left ...

Piper Sandler analyst Scott Siefers maintained a Hold rating on Wells Fargo (WFC – Research Report) today and set a price target of $77.00. The company’s shares closed yesterday at $78.85.

In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Avita Medical (RCEL – Research Report), with a price target of $11.00. The company’s shares closed ...

Piper Sandler Companies reported robust fourth-quarter 2024 earnings, with earnings per share (EPS) of $4.8, surpassing the forecast of $3.93. The company's revenue reached $499 million ...

Olin (NYSE:OLN) on Thursday was downgraded to Neutral from a previous investment rating of Overweight by analysts at financial-services firm Piper Sandler. They said the chemical maker faces ...

Investing.com -- Piper Sandler downgraded Olin Corporation (NYSE:OLN) to "Neutral" from "Overweight" and lowered its price target to $33 from $41, citing a shallower-than-expected earnings recovery ...